Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.

Hurwitz JL, Stasik I, Kerr EM, Holohan C, Redmond KM, McLaughlin KM, Busacca S, Barbone D, Broaddus VC, Gray SG, O'Byrne KJ, Johnston PG, Fennell DA, Longley DB.

Eur J Cancer. 2012 May;48(7):1096-107. doi: 10.1016/j.ejca.2011.11.009. Epub 2011 Dec 10.

PMID:
22154545
2.

SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.

Crawford N, Stasik I, Holohan C, Majkut J, McGrath M, Johnston PG, Chessari G, Ward GA, Waugh DJ, Fennell DA, Longley DB.

Cell Death Dis. 2013 Jul 18;4:e733. doi: 10.1038/cddis.2013.258.

3.

MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.

Yamamoto K, Seike M, Takeuchi S, Soeno C, Miyanaga A, Noro R, Minegishi Y, Kubota K, Gemma A.

Oncol Rep. 2014 Dec;32(6):2365-72. doi: 10.3892/or.2014.3481. Epub 2014 Sep 16.

PMID:
25231602
4.

Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.

Yerbes R, López-Rivas A.

Invest New Drugs. 2012 Apr;30(2):541-7. doi: 10.1007/s10637-010-9597-x. Epub 2010 Nov 25.

PMID:
21107885
5.

Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.

Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, Redmond K, Riley J, McLaughlin K, Stasik I, Crudden M, Van Schaeybroeck S, Fenning C, O'Connor R, Kiely P, Sgobba M, Haigh D, Johnston PG, Longley DB.

Cell Death Differ. 2012 Aug;19(8):1317-27. doi: 10.1038/cdd.2012.8. Epub 2012 Feb 10.

6.

Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.

Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2009 Dec;8(24):2406-16. Epub 2009 Dec 2.

7.
8.

Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

McCourt C, Maxwell P, Mazzucchelli R, Montironi R, Scarpelli M, Salto-Tellez M, O'Sullivan JM, Longley DB, Waugh DJ.

Clin Cancer Res. 2012 Jul 15;18(14):3822-33. doi: 10.1158/1078-0432.CCR-11-3277. Epub 2012 May 23.

9.

SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.

Lauricella M, Ciraolo A, Carlisi D, Vento R, Tesoriere G.

Biochimie. 2012 Feb;94(2):287-99. doi: 10.1016/j.biochi.2011.06.031. Epub 2011 Jul 31.

PMID:
21835222
10.

Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.

Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1115-22. doi: 10.1007/s00280-009-0969-x. Epub 2009 Mar 11.

PMID:
19280190
11.

Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.

Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC.

J Biol Chem. 2008 May 9;283(19):13021-30. doi: 10.1074/jbc.M709698200. Epub 2008 Mar 13.

13.

Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.

Kang Y, Ding M, Tian G, Guo H, Wan Y, Yao Z, Li B, Lin D.

Oncol Rep. 2013 Jul;30(1):313-9. doi: 10.3892/or.2013.2429. Epub 2013 Apr 26.

PMID:
23624653
14.

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.

Linton A, Cheng YY, Griggs K, Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC, Klebe S, van Zandwijk N, Reid G.

Br J Cancer. 2014 Jan 21;110(2):510-9. doi: 10.1038/bjc.2013.731. Epub 2013 Dec 10.

15.

Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.

McLornan D, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK, Johnston PG, Mills KI, McMullin MF, Longley DB, Gilkes A.

Br J Haematol. 2013 Jan;160(2):188-98. doi: 10.1111/bjh.12108. Epub 2012 Nov 20. Erratum in: Br J Haematol. 2013 Aug;162(3):428. Gilkes, Amanda [added].

PMID:
23167276
16.

Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.

Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S.

Lung Cancer. 2007 Jun;56(3):327-36. Epub 2007 Mar 23.

PMID:
17383050
17.

In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.

Hamaguchi N, Hamada H, Miyoshi S, Irifune K, Ito R, Miyazaki T, Higaki J.

Cancer Sci. 2010 Sep;101(9):1955-64. doi: 10.1111/j.1349-7006.2010.01632.x.

18.

Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.

You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.

19.

Triggering of death receptor apoptotic signaling by human papillomavirus 16 E2 protein in cervical cancer cell lines is mediated by interaction with c-FLIP.

Wang W, Fang Y, Sima N, Li Y, Li W, Li L, Han L, Liao S, Han Z, Gao Q, Li K, Deng D, Meng L, Zhou J, Wang S, Ma D.

Apoptosis. 2011 Jan;16(1):55-66. doi: 10.1007/s10495-010-0543-3.

PMID:
20882347
20.
Items per page

Supplemental Content

Write to the Help Desk